Close Menu

NEW YORK – Transplant diagnostics company CareDx said on Wednesday after the close of the market that its preliminary third quarter revenues rose an estimated 57 percent year over year.

For the three months ended Sept. 30, revenues are expected to be approximately $53 million, up from $33.8 million in Q3 2019. Analysts are expecting revenues of $44.7 million for the quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.

In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.

A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.

In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.